

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

Notes of the meeting of the South and West Devon Formulary Interface Group

Tuesday 14th February 2014, 2pm – 4.30pm

The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

Present:	Phil Melliush (PM) – GP– Chair	South Devon & Torbay CCG
	Bill Nolan (BN) – GP	South Devon & Torbay CCG
	Larissa Sullivan (LS) – Interface Pharmacist	NEW Devon CCG
	Gareth Franklin (GF) – Clinical Guidance Manager	NEW Devon CCG
	Iain Roberts (IR) – Lead MO Pharmacist	South Devon & Torbay CCG
	Carol Webb (CW) – Joint Formularies Technician	NEW Devon CCG
	Margaret Hinchliffe (MH)	Lay member
	Paul Manson (PLM) – Lead MO Pharmacist	NEW Devon CCG
	Andrew Gunatilleke (AG1) – Consultant, Chair SDNT DTC	South Devon NHS Trust
	Steve Cooke (SC) – Chief Pharmacist	Plymouth Community Healthcare
	Elena Mercer (EM) – Formulary Pharmacist	NEW Devon CCG
	Karen O’Brien – MO Pharmacist	South Devon & Torbay CCG
Apologies	Keith Gillespie (KG) - GP	NEW Devon CCG
	Sarah Marner (SM) – Interface Pharmacist	NEW Devon CCG
	Chris Roome (CR) – head of Clinical Effectiveness	NEW Devon CCG
	David Gwynne - GP	NEW Devon CCG
	Jeremy Morris (JM) – Formulary Pharmacist	Plymouth Hospitals NHS Trust
	Chris Sullivan (CS) - Pharmacist	Devon Partnership Trust
1	Welcome: Apologies as noted above.	
3	Notes of last meeting 13th December 2013: These were noted and agreed.	
	<p>Action log:</p> <ul style="list-style-type: none"> ● Revised Osteoporosis pathway: A revised drug pathway is being developed by specialists across Devon, to be discussed at a future meeting. ● Antibacterial section: The merge of the BNF entry sections of Chapter 5 is in draft ● Cardiology: LMWH, LS will speak to Rebecca Bell about approved indications for South Devon. The recent draft NICE guideline was noted. ● Pain: <ul style="list-style-type: none"> ○ Matrifen® this is to be discussed in the South Devon GP forum. Still waiting for a response from South Devon Hospice. (post meeting) Dr Jo Sykes (Palliative Care Consultant, SDHCT is happy for Matrifen® to be the fentanyl choice. ○ Targinact® (post meeting note) AG passed on a reply from Dr Jo Sykes who is happy for Targinact® to be specialist initiated ○ Notes for Zomorph® - completed ● Eyes: <ul style="list-style-type: none"> ○ Wording for administration aids – complete ○ Bimatoprost, it was agreed to add both strengths to the formulary ● Epilepsy: It was agreed that advice on consistent brand prescribing is needed but that the 	

issue is very complex

4 Chapter 7 Obstetrics, gynaecology and urinary tract disorders

The merge of this chapter was completed by Tony Perkins, PM presented on his behalf. Comments and outstanding items to be checked:

- Carbetocin
Action: to check if carbetocin is it used in Derriford
- 7.1.1.1 Ductus arteriosus, to follow the BNF format and reference the drugs here but include them in Chapter 2
- Terbutaline – add a summary of the recent MHRA Drug Safety Update on obstetric indications with link
- Estriol cream – 0.1% and 0.01% strengths to be equal first line (green)
- Clotrimazole – to add a reference to the section in chapter 5. To add in the 100mg pessaries for use in pregnancy
- Econazole is not in the primary care guidelines or the HPA guidelines
Action: Check current primary care usage and ask Graham Parsons if there was any discussion during guideline development
- Balance Activ® & Replens MD®- to be amber
- Contraceptive pills – there was discussion around that brands included in regard to the cheaper options. It was agreed to stay with what is already included, add Rigevidon® and change Cerazette® to generic desogestrel
- Ulipristal – to update the note regarding the licensing. To make clear that up to 72 hours levonorgestrel is the formulary choice, that ulipristal is the choice after this.
- South Devon formulary guidance on selecting specific antimuscarinic agents based on symptoms and side-effects to be reviewed for inclusion in SW formulary.
- Bladder installation products

Action: to check which bladder instillation products are used in Derriford

There is a new solifenacin/trospium combined product; interest expressed by specialist in South Devon- to be progressed via appropriate route.

Action: to determine most appropriate route to progress application

5 Chapter 3 Respiratory

The merge of this chapter was done by Karen O'Brien who presented the chapter to the committee. Comments and outstanding items to be checked:

- Ipratropium bromide – to delete the asthma indication
- Theophylline
 - To delete the asthma indication
 - To delete the 200mg daily for 4 days at the start of the initiation guidance for Uniphyllin®
 - 60mg/5mL liquid – not used in South Devon, is this used in Derriford
Action: to check if theophylline 60mg/5mL is used in Derriford
- Corticosteroid inhalers – to define high, medium and low dose corticosteroids in terms of

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

beclometasone equivalent

- LABA / ICS combination inhalers - to remain blue
- Grazax – it was agreed that there is no monitoring to be done for this drug and that there is no need for Shared Care. There is only Shared care for this in the Plymouth area at the moment

Action: To discuss variations in Shared Care within the formulary area with Chris Roome

- Adrenaline - the dose for under 6 months of age should be 150 micrograms
- N-Acetyl cysteine – there was discussion about the prescribing of this product.

6 Dermatology questions:

Dr NG Sheau from Torbay Hospital has asked if ingenol (Picato®) could be reclassified as a second line drug as in the rest of Devon, currently red in the South Devon Formulary. Dr Ng also requested imiquimod 5% (Aldara®) be reclassified from hospital only to specialist. This was discussed and it was felt that more information was needed. The merge of the dermatology chapter is currently underway

7 Recent drug decisions including NICE

These were noted

- Loperamide melts: a consultant in Derriford has asked that these be included into the formulary. This was discussed and it was felt that more information is needed.

There was discussion at this point as what information from the specialists is would be needed for an application submitted to the formulary groups for a decision to be made. Suggestions were the number of patients, cost, place in treatment and the opinion of both the hospital trusts.

Action: to produce a check list of points for discussion at FIG

8 MHRA Drug Safety Update – December, January

These were noted

Any other business

- AG noted that there is some new guidance forthcoming about medication reviews in the elderly, could this information be added into the formulary.

Action: to add guidance on medication reviews in the elderly to an agenda when available

- There was discussion regarding a launch date for the new South and West Formulary, it was decided to aim for the beginning of June. Further hosting fees would be due after June for the current Plymouth Formulary.

Next meeting: Friday 14th March 2014 2pm – 4:30pm The Watermark, Ivybridge PL21 0SZ

Northern, Eastern & Western Devon Clinical Commissioning Group
South Devon and Torbay Clinical Commissioning Group

South and West Devon Formulary Group – Action log			
Date	Action	Responsible	Completed
June 2013	To bring a revised osteoporosis pathway to future meeting	GF	
Sept 2013	An update on the dressings project to be given to the meeting after the next dressings meeting	TM	
Sept 2013	Updated ToR for discussion – future meeting	GF	
Dec 2013	Cardiology: <ul style="list-style-type: none"> • LMWH, waiting for this to be discussed 	LS	
Dec 13	Brand names for epilepsy treatments <ul style="list-style-type: none"> • To ask Rebecca Bell to brief the committee on this when available 	IR	
Feb 14	Chapter 7 Obstetrics, gynaecology and urinary tract disorders <ul style="list-style-type: none"> • check primary care usage of Econazole and ask Graham Parsons if there was any discussion on this drug • to check if carbetocin is it used in Derriford • to check which bladder instillation products are used in Derriford • to determine most appropriate route to progress solifenacin/trospium application 	GF CW CW GF	Yes- minimal use Not used Checked and noted
Feb 14	Chapter 3 Respiratory <ul style="list-style-type: none"> • to check if theophylline 60mg/5mL is used in Derriford • to discuss variations in Shared Care within the formulary area with Chris Roome 	CW GF	Yes
Feb 14	To produce a formulary group check list to enable discussions at FIG	GF	
Feb 14	To add guidance on medication reviews in the elderly to an agenda when available	AG	